PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-26.14%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-26.43%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-26.52%
Negative EPS growth while AXSM is at 3.13%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-26.52%
Negative diluted EPS growth while AXSM is at 3.13%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.09%
Share reduction more than 1.5x AXSM's 2.07%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.09%
Diluted share reduction more than 1.5x AXSM's 2.07%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-57.07%
Negative OCF growth while AXSM is at 22.89%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-57.72%
Negative FCF growth while AXSM is at 22.88%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13659.85%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
12.78%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
32.48%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-18544.23%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
7.55%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
44.34%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
1862.49%
Equity/share CAGR of 1862.49% while AXSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
309.42%
Equity/share CAGR of 309.42% while AXSM is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-81.93%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.47%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-33.19%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
26.95%
R&D growth drastically higher vs. AXSM's 8.83%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
24.63%
We expand SG&A while AXSM cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.